H2Biologics is a biotechnology company designing novel proteins for cancers such as pancreatic, ovarian, lung, and mesothelioma that continue to have poor survival rates and prognoses. The success of the Company’s therapeutic approach is based on safely delivering naturally occurring human Granzyme B, a high-powered cytotoxic molecule employed by the immune system to kill target cells. This strategy maximizes anti-tumor efficacy while minimizing the safety concerns encountered with other immunotoxins.